This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal
Events & Webinars

Evolving mCRPC treatment landscape in 2023

Xofigo Header Image

Description

The field of prostate cancer treatment is undergoing rapid evolution, with a noticeable shift towards earlier administration of therapies in the treatment pathway. These advancements have resulted in substantial changes in the approach to treating patients with metastatic castration-resistant prostate cancer (mCRPC).

In this on-demand webinar,

Professor Joe O'Sullivan
provides valuable insights into the positioning of Radium-223 within the treatment pathway and offers recommendations for optimising the sequencing of available treatments. Following Professor O'Sullivan,
Dr. Matt Aldridge
 offers an overview of how to establish and enhance a Radium-223 service, drawing from his experience at Maidstone and Tunbridge Wells NHS Trust.

Interested in learning more? Watch the video below.

This promotional webinar was organised and funded by Bayer plc.

Xofigo
▼
Prescribing Information

Speakers

BNMS 2024
Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
PP-XOF-GB-0598, January 2025

PP-XOF-GB-0505 | February 2024